Hot Investor Mandate: China-Based Investment Company Invests in Early-Stage Life Science Investment Opportunities with China Angle, with Capacity to Invest Over $10M

27 Nov

An investment company with base operations in China manages a¥3000M fund. The typical allocation size of the firm ranges from ¥50M to ¥100M (~$7 to 14M USD). The firm is generally interested in companies in therapeutics, medical devices, diagnostics, and healthcare IT areas.

The firm is interested in the medical device, diagnostics, and Healthcare IT companies. Within the therapeutics sector, the firm will mainly look at CRO and CDMO companies and it prefers companies with unique R&D platforms. The firm will look at companies that are in development and it is most interested in companies that are closed to commercialize or are already on the market. The firm prefers to invest in early-stage companies that are FDA/CE/NMPA approved or are closed to getting NMPA approval. The firm is willing to help its portfolio companies to expand their commercialization in Chinese market.

The firm prefers companies from China, but will also invest in foreign companies with China angles or China market or those who have branches in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: